Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

    Mario E. Lacouture, V. Sibaud
    Image of study
    TLDR Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
    The document reviewed the dermatologic adverse events (dAEs) associated with targeted therapies and immunotherapies used in cancer treatment, highlighting the impact on skin, oral mucosa, hair, and nails. Acneiform rash was the most common skin toxicity, while BRAF inhibitors were associated with secondary skin tumors and alopecia. Oral mucositis was frequently caused by mTOR inhibitors, and immune checkpoint inhibitors often led to oral lichenoid reactions. The document emphasized the significant impact of these toxicities on patients' quality of life and treatment adherence, underscoring the importance of management strategies, including prophylactic measures like dexamethasone-based mouthwash, which was shown in the SWISH trial to reduce the incidence of stomatitis. It concluded that collaboration between dermatologists and oncologists is essential for managing these side effects to maintain treatment adherence and improve patient outcomes.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 1000+ results

      community What else is good. Besides the big 3.

      in Chat  34 upvotes 2 months ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community Why is everyone not directly advised Dutasteride?

      in Finasteride/Dutasteride  167 upvotes 2 months ago
      Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Similar Research

    5 / 1000+ results